|
| 37767674 | Contemporary Use and Implications of Beta-Blockers in Patients With HFmrEF or HFpEF: The DELIVER Trial. | JACC Heart Fail | 2024 |
| 36342789 | Sex Differences in Characteristics, Outcomes, and Treatment Response With Dapagliflozin Across the Range of Ejection Fraction in Patients With Heart Failure: Insights From DAPA-HF and DELIVER. | Circulation | 2023 |
| 37635157 | Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial. | Nat Med | 2023 |
| 37634707 | Dapagliflozin in Patients With Heart Failure and Deterioration in Renal Function. | J Am Coll Cardiol | 2023 |
| 37755728 | Prevalence and Overlap of Cardiac, Renal, and Metabolic Conditions in US Adults, 1999-2020. | JAMA Cardiol | 2023 |
| 37632711 | Influence of background medical therapy on efficacy and safety of dapagliflozin in patients with heart failure with improved ejection fraction in the DELIVER trial. | Eur J Heart Fail | 2023 |
| 37632455 | Outpatient Worsening Among Patients With Mildly Reduced and Preserved Ejection Fraction Heart Failure in the DELIVER Trial. | Circulation | 2023 |
| 37558385 | Effect of Sotagliflozin on Early Mortality and Heart Failure-Related Events: A Post Hoc Analysis of SOLOIST-WHF. | JACC Heart Fail | 2023 |
| 37622681 | Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. | N Engl J Med | 2023 |
| 37610398 | Efficacy of Dapagliflozin According to Geographic Location of Patients With Heart Failure. | J Am Coll Cardiol | 2023 |
| 37830208 | Dapagliflozin and Apparent Treatment-Resistant Hypertension in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The DELIVER Trial. | Circulation | 2023 |
| 37643614 | A big STEP for treatment of heart failure with preserved ejection fraction. | Cell Metab | 2023 |
| 37771274 | Impact of COVID-19 in patients with heart failure with mildly reduced or preserved ejection fraction enrolled in the DELIVER trial. | Eur J Heart Fail | 2023 |
| 37498273 | Association Between Wearable Device Measured Activity and Patient-Reported Outcomes for Heart Failure. | JACC Heart Fail | 2023 |
| 37565953 | Impact of SGLT2 Inhibitors on AF Recurrence After Catheter Ablation in Patients With Type 2 Diabetes. | JACC Clin Electrophysiol | 2023 |
| 37220822 | Operational challenges and mitigation measures during the COVID-19 pandemic-Lessons from DELIVER. | Am Heart J | 2023 |
| 37220172 | Heart failure, peripheral artery disease, and dapagliflozin: a patient-level meta-analysis of DAPA-HF and DELIVER. | Eur Heart J | 2023 |
| 37220093 | Dapagliflozin and diuretic utilization in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial. | Eur Heart J | 2023 |
| 37191040 | Racial Differences in Quality of Life in Patients With Heart Failure Treated With Sodium-Glucose Cotransporter 2 Inhibitors: A Patient-Level Meta-Analysis of the CHIEF-HF, DEFINE-HF, and PRESERVED-HF Trials. | Circulation | 2023 |
| 37423628 | Diabetes status and other factors as correlates of risk for thrombotic and thromboembolic events during SARS-CoV-2 infection: A nationwide retrospective case-control study using <i>Cerner Real-World Dataâ¿¢</i>. | BMJ Open | 2023 |
| 37055714 | Lower risk of cardiovascular events and death associated with initiation of sodium-glucose cotransporter-2 inhibitors versus sulphonylureas: Analysis from the CVD-REAL 2 study. | Diabetes Obes Metab | 2023 |
| 37318419 | Dapagliflozin and Physical and Social Activity Limitations in Heart Failure With Reduced Ejection Fraction. | JACC Heart Fail | 2023 |
| 37212168 | Renal and blood pressure effects of dapagliflozin in recently hospitalized patients with heart failure with mildly reduced or preserved ejection fraction: Insights from the DELIVER trial. | Eur J Heart Fail | 2023 |
| 37211977 | Effect of dapagliflozin on health status and quality of life across the spectrum of ejection fraction: Participant-level pooled analysis from the DAPA-HF and DELIVER trials. | Eur J Heart Fail | 2023 |
| 37344038 | Effect of SGLT2 Inhibitors on Cardiovascular Outcomes Across Various Patient Populations. | J Am Coll Cardiol | 2023 |
| 37210608 | Effects of dapagliflozin on heart failure hospitalizations according to severity of inpatient course: Insights from DELIVER and DAPA-HF. | Eur J Heart Fail | 2023 |
| 37208998 | Association of Dapagliflozin vs Placebo With Individual Kansas City Cardiomyopathy Questionnaire Components in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Secondary Analysis of the DELIVER Trial. | JAMA Cardiol | 2023 |
| 37178991 | Biomarkers for the Diagnosis of Heart Failure in People with Diabetes: A Consensus Report from Diabetes Technology Society. | Prog Cardiovasc Dis | 2023 |
| 37407113 | Association of Carbohydrate Antigen 125 on the Response to Dapagliflozin in Patients With Heart Failure. | J Am Coll Cardiol | 2023 |
| 37039015 | Endothelin-1, Outcomes in Patients With Heart Failure and Reduced Ejection Fraction, and Effects of Dapagliflozin: Findings From DAPA-HF. | Circulation | 2023 |
| 37038330 | The win ratio method in heart failure trials: lessons learnt from EMPULSE. | Eur J Heart Fail | 2023 |
| 37401511 | Impact of comorbidities on health status measured using the Kansas City Cardiomyopathy Questionnaire in patients with heart failure with reduced and preserved ejection fraction. | Eur J Heart Fail | 2023 |
| 37203441 | Dapagliflozin Improves Heart Failure Symptoms and Physical Limitations Across the Full Range of Ejection Fraction: Pooled Patient-Level Analysis From DEFINE-HF and PRESERVED-HF Trials. | Circ Heart Fail | 2023 |
| 37230315 | Association Between Change in Ambulatory Pulmonary Artery Pressures and Natriuretic Peptides in Patients with Heart Failure: Results From the EMBRACE-HF Trial. | J Card Fail | 2023 |
| 37099283 | Effect of Dapagliflozin on Total Heart Failure Events in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the DELIVER Trial. | JAMA Cardiol | 2023 |
| 37227729 | Effect of P2Y12 Inhibitors on Organ Support-Free Survival in Critically Ill Patients Hospitalized for COVID-19: A Randomized Clinical Trial. | JAMA Netw Open | 2023 |
| 37164146 | Contemporary use of cardiovascular risk reduction strategies in type 2 diabetes. Insights from the diabetes collaborative registry. | Am Heart J | 2023 |
| 37294245 | Design and Baseline Characteristics of STEP-HFpEF Program Evaluating Semaglutide in Patients With Obesity HFpEF Phenotype. | JACC Heart Fail | 2023 |
| 37294244 | Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction According to Polypharmacy Status. | JACC Heart Fail | 2023 |
| 37226448 | Cardio-Renal-Metabolic Overlap, Outcomes, and Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction. | JACC Heart Fail | 2023 |
| 37356038 | Effect of the P-Selectin Inhibitor Crizanlizumab on Survival Free of Organ Support in Patients Hospitalized for COVID-19: A Randomized Controlled Trial. | Circulation | 2023 |
| 36592046 | IGFBP-7 and Outcomes in Heart Failure With Reduced Ejection Fraction: Findings From DAPA-HF. | JACC Heart Fail | 2023 |
| 36881399 | Dapagliflozin in Black and White Patients With Heart Failure Across the Ejection Fraction Spectrum. | JACC Heart Fail | 2023 |
| 36811901 | Association of Dapagliflozin Use With Clinical Outcomes and the Introduction of Uric Acid-Lowering Therapy and Colchicine in Patients With Heart Failure With and Without Gout: A Patient-Level Pooled Meta-analysis of DAPA-HF and DELIVER. | JAMA Cardiol | 2023 |
| 36876483 | Patient Characteristics, Outcomes, and Effects of Dapagliflozin According to the Duration of Heart Failure: A Prespecified Analysis of the DELIVER Trial. | Circulation | 2023 |
| 36913500 | Response by Selvaraj et al to Letter Regarding Article, "Metabolomic Profiling of the Effects of Dapagliflozin in Heart Failure With Reduced Ejection Fraction: DEFINE-HF". | Circulation | 2023 |
| 36843558 | Use of optimal medical therapy in patients with diabetes and atherosclerotic cardiovascular disease: Insights from a prospective longitudinal cohort study. | Diabetes Obes Metab | 2023 |
| 36932245 | Author Correction: Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial. | Nat Med | 2023 |
| 36868222 | Sustained alternate-day fasting potentiates doxorubicin cardiotoxicity. | Cell Metab | 2023 |
| 36796312 | Patterns of new glucagon-like peptide-1 receptor agonist use in patients with type 2 diabetes during 2014-2019 from a US database: prescriber and patient characteristics. | J Diabetes | 2023 |